Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL

Although the tyrosine kinase inhibitor imatinib has been shown to be an active agent in patients with gastrointestinal stromal tumours (GIST), complete remissions are almost never seen and most patients finally experience disease progression during their course of treatment. An alternative therapeutic option is to target death receptors such as Fas. We showed that a panel of imatinib-sensitive (GIST882) and imatinib-resistant (GIST48, GIST430 and GIST430K-) cell lines expressed Fas. MegaFasL, a recently developed hexameric form of soluble Fas ligand (FasL), appeared to be an active apoptosis-inducing agent in these cell lines. Moreover, MegaFasL potentiated the apoptotic effects of imatinib. Immunohistochemical evaluations, in 45 primary GISTs, underscored the relevance of the Fas pathway: Fas was expressed in all GISTs and was expressed strongly in 93%, whereas FasL was expressed at moderate and strong levels in 35 and 53% of GISTs, respectively. Fas and FasL expression were positively correlated in these primary GISTs, but there was no association between Fas or FasL expression and primary site, histological subtype, tumour size, mitotic index, risk classification, and KIT mutation status. The abundant immunohistochemical Fas and FasL expression were corroborated by western blot analysis. In conclusion, our data implicate Fas as a potential therapeutic target in GIST.

Keywords: gastrointestinal stromal tumour; Fas; Fas ligand; imatinib; MegaFasL

The observation that nearly all spindle cell and epithelial tumours of the stomach and bowel highly express the receptor tyrosine kinase KIT has led to the characterisation of gastrointestinal stromal tumours (GISTs) as a distinct clinicopathological entity different from other gastrointestinal mesenchymal tumours. Various KIT genomic mutations occur in about 80% of GISTs. In addition, about 5% of GISTs have mutations in the platelet-derived growth factor receptor-α (PDGFRα) (Corless et al., 2004). These mutations lead to ligand-independent activation of KIT or PDGFRα, which plays an essential role in the development and progression of GIST (Heinrich et al., 2002, 2003). As GISTs are insensitive to conventional chemotherapy, the introduction of imatinib, a small-molecule receptor tyrosine kinase inhibitor active against KIT and PDGFRα, has been a major therapeutic breakthrough. Imatinib therapy has dramatically improved the survival of patients with unresectable or metastatic GIST (Verweij et al., 2004). Imatinib therapy has dramatically improved the survival of patients with unresectable or metastatic GIST (Verweij et al., 2004). Despite these successes, about 10% of the patients show initial resistance to imatinib. Moreover, complete remissions are almost never seen and most patients experience disease progression after a median period of approximately 2–3 years (Verweij et al., 2004). To date, sunitinib, an inhibitor of multiple receptor tyrosine kinases including KIT, PDGFRα, vascular endothelial growth factor receptor (VEGFR), and fms-related tyrosine kinase 3 (FLT3), is used as a second-line treatment providing clinical benefit in patients with imatinib-resistant GIST for a limited time period (Judson and Demetri, 2007). However, there is urgent need for the development of new therapeutics acting through pathways complementary to those targeted by KIT kinase inhibitors such as imatinib and sunitinib.

Fas (CD95) and Fas ligand (FasL; CD95L) belong to the TNF family of death receptors and ligands (Itoh et al., 1991; Suda et al., 1993). At the molecular level, binding of FasL to Fas induces receptor trimerisation, followed by the binding of Fas-associated death domain (FADD) with caspase 8 and/or 10 to the intracellular death domain of Fas. Caspase activation within this complex initiates cleavage and activation of an intracellular cascade of effector caspsases (e.g., caspases 3, 6, and 7), eventually in cleavage of specific death substrates and apoptosis (Timmer et al., 2002). Thus, in tumours expressing Fas, targeting of Fas-mediated apoptosis could be a promising therapy. Although many in vitro and in vivo cancer models have shown sensitivity towards Fas agonistic antibodies, clinical application of these antibodies is hampered because of severe liver toxicity (Ogasawara et al., 1993). Furthermore, resistance to Fas-mediated apoptosis because of inhibitory mechanisms along the apoptotic signalling pathway has
been observed in other cancer models (Houston and O’Connell, 2004). Soluble forms of FasL (sFasL) are potentially toxic (Schneider et al., 1998), and a hexameric form of sFasL, produced by fusing the dimer-forming serum protein stalk of human ACRP30 to the trimeric portion of human FasL, has recently been developed. This compound, called MegaFasL, is more cytotoxic to tumour cells compared to trimeric sFasL (Holler et al., 2003; Greaney et al., 2006; Etter et al., 2007). MegaFasL is currently tested in a phase-I clinical trial (ClinicalTrials.gov identifier: NCT00437736).

This study was initiated given the lack of data on expression of Fas and FasL in GIST. Therefore, the sensitivity of GIST cell lines towards Fas activation and the potentiating effect of imatinib on this activation were investigated. In addition, the expression of Fas and FasL in primary GIST samples was studied. Together, these data implicate Fas as a potential therapeutic target in GIST.

MATERIALS AND METHODS

Cell culture

The GIST cell line GIST882 was developed from a primary, untreated, GIST, with a homozygous KIT exon 13 mutation (Tuveson et al., 2001). Cells were maintained in RPMI 1640 (Invitrogen, Praisley, UK) supplemented with 15% heat inactivated fetal calf serum (FCS; Bodinco, Alkmaar, The Netherlands) and 1 mM l-glutamine (Invitrogen). The GIST cell lines GIST48 and GIST430 were established from tumours that were progressive during imatinib therapy after an initial clinical response (Bauer et al., 2006). GIST48 harbours a homozygous primary KIT exon 11 mutation and a heterogeneous secondary exon 17 mutation. GIST430 has a heterogeneous primary KIT exon 11 and a secondary heterogeneous exon 13 mutation. The KIT-negative GIST430K- cell line was derived from GIST430 cells. The GIST48 and GIST430 cells were maintained in F-10 (Invitrogen) supplemented with 10 and 15% FCS, respectively, and 0.5% mito- + serum extender (VWR International, Roden, The Netherlands) and 1% bovine pituitary extract (VWR International). The cervical carcinoma cell line HeLa was maintained in 1 : 1 DMEM/HAM supplemented with 10% FCS.

Flow cytometry

Fas membrane expression was determined in GIST cells by flow cytometry as described previously (De Groot et al., 2005). Phycocerythrin (PE)-conjugated mouse anti-Fas monoclonal antibody (clone DX-2, 1 : 10; BD Pharmingen, Alphen aan den Rijn, The Netherlands) and PE-conjugated mouse IgG1 (BD Pharmingen) served as an isotype control.

Acridine orange apoptosis assay

Cells were treated with MegaFasL (kindly provided by Apoxis, Lausanne, Switzerland) for 6 h. To investigate the effect of MegaFasL on imatinib-induced apoptosis, cells were pretreated with imatinib (kindly provided by Novartis, Basel, Switzerland) for 24 h followed by 24 h incubation with MegaFasL without removing imatinib. Alternatively, cells were first treated with MegaFasL for 24 h with subsequent treatment with imatinib for 24 h. Control cells were incubated with DMSO, which was used as a solvent for imatinib, where appropriate, or a single drug. After these treatments, acridine orange (10 µg ml⁻¹) was added to each well to distinguish apoptotic cells from vital cells. Apoptosis was defined as the appearance of apoptotic bodies and/or chromatin condensation, using a fluorescence microscope. Results were expressed as the percentage of apoptotic cells in a culture by counting at least 300 cells per well. All apoptosis assays were performed three times in duplicate.

Western blot analysis

After treatment with MegaFasL, as described above, GIST882 and GIST48 cells were lysed and the protein concentration was determined according to the Bradford method. Western blotting was performed as described previously (De Groot et al., 2003). Primary antibodies were goat anti-Fas (polyclonal, 1 : 400; Santa Cruz, Heerhugowaard, The Netherlands), mouse anti-FasL, and mouse anti-caspase 8 (clone 8C12, 1 : 1000; BD Transduction Laboratories, Alphen aan den Rijn, The Netherlands), rabbit anti-cleaved caspase 3 and rabbit anti-caspase 6 (1 : 1000; Cell Signalling Technology, Biozé, Leiden, The Netherlands), mouse anti-caspase 8 (clone 1C12, 1 : 500; Cell Signalling), and mouse anti-actin (clone C4, 1 : 20 000; ICN Biomedicals, Zoetermeer, The Netherlands).

Tissue collection

The study group consisted of 45 primary GISTs derived from 44 patients. Paraffin-embedded tumour tissues of primary GISTs were retrieved from the files of the Department of Pathology of the University Medical Center Groningen. Tumours were surgically resected between 1985 and 2005. All tumours were reviewed by a pathologist with special expertise in soft tissue tumours (AJHS). The diagnosis of GIST was based on the typical histological features of a cellular spindle cell or epithelioid mesenchymal tumour of the gastrointestinal tract. In addition, all tumours were positive for CD117 (KIT) by immunohistochemistry. Tumours were categorised into risk groups based on tumour size and mitotic index, according to the consensus classification for prediction of metastatic potential (Fletcher et al., 2002). Tumour size was obtained from the pathology reports. Mitotic index was counted in 50 consecutive high power fields (× 40 objective; field diameter 0.55 mm). Clinicopathological data collected included sex and age of the patient at diagnosis, primary tumour site, and histological subtype. For the detection of KIT mutations, genomic DNA was extracted from paraffin-embedded tumour samples and KIT exon 9 or 11 was amplified by PCR. Both forward and reverse PCR products were sequenced and the results were compared with normal sequences. One patient had two primary GISTs, which were a high risk epithelioid gastric tumour lacking a KIT exon 9 and 11 mutation and a low risk spindle-cell small intestine tumour with a KIT exon 9 mutation, respectively. Patient and tumour characteristics are summarised in Table 1.

For the detection of Fas and FasL by western blotting, six frozen primary GIST samples were pulverised and dissolved in ice-cold PBS. After centrifugation at 18 000 g for 1 min to remove debris, the supernatant was collected. Western blot analysis was performed as described above.

All tumour samples used in this study were handled according to the guidelines of the Dutch Federation of Biomedical Scientific Societies (FMWV) as described in ‘Code Proper Secondary Use of Human Tissue’.

Tissue microarray construction

Representative regions of the paraffin-embedded primary tumours were selected using H&E-stained slides and arrayed into a tissue microarray (TMA), as described previously (Westrä et al., 2005). Briefly, three 0.6 mm tissue cores were taken from (distinct) representative areas of each tumour specimen using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA) and then transferred to a standard-size recipient paraffin block. The array contained 161 tissue cores including 45 tumour samples in triplicate and 13 normal tissues in duplicate, the latter serving as an internal control for immunohistochemistry.
Translational Therapeutics

0.2% SDS in maleic acid buffer (pH 6.0) at 115°C for three times. Primary antibodies were mouse anti-Fas (clone CH-11, 1:100; Upstate Biotechnology, Lake Placid, NY, USA) and mouse anti-Fasl (clone 33, 1:160; BD Transduction Laboratories). As a negative control, a serial section was processed without the addition of primary antibody. Normal tissue samples within the TMA block served as negative control, a serial section was processed without the addition of primary antibody.

Staining analysis

Immunohistochemistry results were scored independently by two observers (BR and AJHS) without knowledge of the clinicopathological data. As in each individual core all tumour cells showed the same staining, cores were scored in a semiquantitative manner for staining intensity: no staining (0), weakly positive staining (1), positive staining (2), strong positive staining (3). Discrepant scoring results were discussed under a multiehead microscope to achieve consensus. If cores from one tumour differed in staining intensity, the median score of the three related cores determined the score of the tumour. Furthermore, the staining pattern was determined from each core.

Statistical analysis

Data analysis was performed using SPSS 12.0 software package for Windows (SPSS Inc., Chicago, IL, USA). Differences in distributions of Fas or Fasl staining intensity and the different tumour characteristics were evaluated by the χ² test. To determine the correlation between Fas and Fasl staining, the spearman’s rank test was used. A two-tailed P-value <0.05 was considered to be significant.

RESULTS

MegaFasL-induced apoptosis in GIST cells

To evaluate whether Fas could be used as a target in GIST, we first investigated Fas membrane expression in a panel of imatinib-sensitive (GIST882) and imatinib-resistant (GIST48, GIST430 and GIST430K-) cell lines. The cervical carcinoma cell line HeLa is sensitive to MegaFasL and was used as positive control (Holler et al., 2003). Flow cytometry analysis revealed that all the GIST cell lines had a high level of Fas membrane expression (Figure 1A). We therefore tested the effectiveness of MegaFasL, a hexameric form of sFasL. After as little as 6 h of MegaFasL treatment, dose-dependent apoptosis was observed in all the GIST cell lines. MegaFasL induced substantially higher levels of apoptosis in GIST882, GIST430, and GIST430K- than in HeLa, while nearly equal amounts were observed in GIST48 compared to HeLa (Figure 1B and C). Treatment of GIST882 and GIST48 with MegaFasL resulted in caspase 8 activation and the disappearance of the inactive proform of caspases 3 and 6. The active p19/p17 fragments of caspase 3 were detected in both cell lines, although to a lesser extent in GIST48, which is in agreement with the observed difference in apoptosis levels between these two cell lines when treated with 50 ng ml⁻¹ MegaFasL (53% apoptosis in GIST882 and 25% in GIST48; Figure 1C and D). The effect of MegaFasL was dependent on caspase activation as zVAD-fmk, a pan-caspase inhibitor, completely blocked apoptosis induction by this compound (data not shown).

The effect of MegaFasL on imatinib-induced apoptosis

Following the identification of MegaFasL as a potent apoptosis-inducing agent in GIST cells, we investigated its effect in combination with imatinib. GIST882 pretreatment with MegaFasL followed by the addition of imatinib, appeared to be the most effective schedule. In this way, low concentrations of MegaFasL for 24 h followed by the addition of imatinib for another 24 h substantially increased the amount of apoptosis compared to levels seen with either MegaFasL or imatinib treatments alone (Figure 2A). When imatinib was administered before MegaFasL, no synergistic but rather an additive effect was observed (data not shown).

Recently, Bauer et al. (2006) showed that GIST48 cells are relatively resistant towards imatinib. We therefore also evaluated the combination of MegaFasL and imatinib in GIST48 by using the same treatment schedule as GIST882. As in GIST882, synergistic apoptosis induction was seen for the combination of MegaFasL and imatinib, although higher concentrations of MegaFasL were necessary to induce a substantial amount of apoptosis (Figure 2B).

Fas and Fasl expression in GIST by immunohistochemistry

As MegaFasL appeared to be an active agent in GIST cells, we studied the expression of Fas and Fasl in 45 GIST samples by

---

Table I Patient (n = 44) and tumour (n = 45) characteristics

| Characteristic     | n (%)       |
|--------------------|-------------|
| Sex                |             |
| Male               | 19 (43)     |
| Female             | 25 (57)     |
| Age (years), median (range) | 65.5 (36–87) |
| Risk classification|             |
| Very low risk      | 4 (9)       |
| Low risk           | 13 (29)     |
| Intermediate risk  | 13 (29)     |
| High risk          | 15 (33)     |
| Primary site       |             |
| Stomach            | 29 (64)     |
| Small intestine    | 12 (27)     |
| Colon              | 7 (16)      |
| Unknown            | 1 (2)       |
| Histology          |             |
| Spindle cell       | 37 (82)     |
| Epithelioid        | 7 (16)      |
| Mixed              | 1 (2)       |
| Tumour size        |             |
| ≤5 cm              | 19 (42)     |
| 5–10 cm            | 17 (38)     |
| >10 cm             | 9 (20)      |
| Mitotic figures    |             |
| ≤5 per 50 HPF      | 38 (84)     |
| >5 per 50 HPF      | 7 (16)      |
| KIT mutation       |             |
| Exon 11 mutation   | 28 (62)     |
| Exon 9 mutation    | 1 (2)       |
| No exon 11 or 9 mutation | 15 (33) |
| Unknown            | 1 (2)       |

Abbreviation: HPF = high power fields.
immunohistochemistry using a TMA. Table 2 shows the overall staining characteristics of Fas and FasL in the 45 GISTs tested. Fas was detectable in all the tumour samples studied and was strongly expressed in 62%. FasL expression was discerned in 89% of the tumours with 27% staining strongly positive. A significant correlation between Fas and FasL expression was found (Spearman's correlation coefficient $r = 0.4$, $P = 0.006$). Further statistical analysis revealed that Fas and FasL staining intensity was not associated with (1) risk classification, (2) primary site, (3) histological subtype, (4) tumour size, (5) mitotic index, and (6) KIT mutation status.

Both Fas and FasL immunohistochemical staining was predominantly cytoplasmic. The staining pattern for Fas was diffuse, in contrast to FasL, which was mainly granular (Figure 3).
Fas and FasL expression in GIST by western blot analysis

In addition to immunohistochemistry, Fas and FasL protein expression in six GIST samples and the GIST882 cell line was evaluated by western blot analysis. HeLa was used as a positive control (Hougardy et al., 2005). As shown in Figure 4, protein products corresponding to the predicted molecular mass of ~36 kDa for FasL, were detected in HeLa, GIST882, and in all six GISTs. The ~48 kDa Fas protein product was also detectable in GIST882 and in all GIST samples. Furthermore, most GIST samples – as well as the HeLa cell line – showed a lower band of ~43 kDa. In addition, most of the GISTS featured an additional band that migrated more slowly than the two bands shown in HeLa (Figure 4). This additional ~52 kDa band could represent a highly sialylated but functional form of Fas (Oehm et al., 1992; Keppler et al., 1999).

DISCUSSION

The results of this study indicate that Fas may be a promising therapeutic target in GIST. The GIST cell lines in our panel were found to be highly sensitive to MegaFasL, which proved to be an active apoptosis-inducing agent. Moreover, MegaFasL sensitised GIST cells to imatinib-induced apoptosis. In addition to these in vitro data, we found that each of 45 primary GISTs expressed Fas, and most expressed FasL.

This is the first study investigating the role of death receptors in the treatment of GIST. Both imatinib-sensitive (GIST882) and imatinib-resistant GIST cell lines (GIST48, GIST430, and GIST430K-) were responsive to MegaFasL. Furthermore, MegaFasL sensitivity appeared to be independent of KIT expression because the GIST430 cell line that expresses KIT was as sensitive to MegaFasL as its KIT-negative daughter cell line. We found that low concentrations of MegaFasL sensitised GIST cells to imatinib-induced apoptosis. Notably, it appeared that the sequence of drug delivery was important. Pretreatment of cells with imatinib followed by incubation with MegaFasL had no more than an additive effect. Reversing this schedule, however, resulted in synergistic apoptosis induction. The underlying mechanism for this observation remains unclear. Nimmanapalli et al. (2001) showed that the sensitising effect of imatinib to TRAIL in Bcr-Abl-positive leukaemia cells was reduced when TRAIL was administered after exposure to imatinib. Although imatinib causes cell cycle arrest, it is unlikely that this mechanism is involved in the reduced potentiation of MegaFasL-induced apoptosis by imatinib pretreatment, as Fas-mediated apoptosis is not cell cycle dependent (Hueber et al., 1998; Tepper et al., 2000). Possibly, KIT inhibition by imatinib alters the membrane distribution of Fas, making it less accessible for MegaFasL. Alternatively, the activated caspase cascade by MegaFasL may induce cleavage of proteins involved in cellular resistance to imatinib.

In our patient cohort, which was representative for an unselected GIST population with regard to sex, age, tumour localisation, histology, risk classification, and KIT exon 11 mutations (Corless et al., 2004; Nilsson et al., 2005), Fas and FasL were abundantly expressed. Western blot analysis confirmed these findings. Acquisition of FasL expression by tumour cells is one of the mechanisms involved in tumour immune escape. Various tumour types have been reported to express FasL, which can be negatively correlated with prognosis as described for colon and breast carcinomas (Reimer et al., 2000; Belluco et al., 2002). In our study, 89% of the GISTs expressed FasL, but no correlation was observed in many other tumour types as well (Arts et al., 2003; Houston and O’Connell, 2004). Further studies are needed to determine whether such mechanisms also apply in GIST.

### Table 2 Expression of Fas and FasL in GIST

| Staining intensity | Fas, n (%) | FasL, n (%) |
|--------------------|------------|------------|
| 0                  | 0 (0)      | 5 (11)     |
| 1                  | 3 (7)      | 16 (36)    |
| 2                  | 14 (31)    | 12 (27)    |
| 3                  | 28 (62)    | 12 (27)    |
| Total              | 45 (100)   | 45 (100)   |

Figure 2 The effect of MegaFasL on imatinib-induced apoptosis. (A) GIST882 cells were pretreated with MegaFasL, as indicated, for 24 h followed by incubation with either DMSO-only or 1 μM imatinib for an additional 24 h. Apoptosis was determined by acridine orange staining. (B) GIST48 cells were treated with MegaFasL and/or imatinib, as described in (A). Data represent the mean ± s.d. of three independent experiments.
Gastrointestinal stromal tumour patients generally respond to therapy with imatinib, which inhibits the KIT and PDGFRA oncoproteins that appear to be initiating oncogenic events in most GISTs. However, in the long run, most patients develop resistance to imatinib therapy, as manifested by tumour progression. It appears that, although imatinib treatment induces apoptosis and causes cell cycle arrest of GIST cells, a fraction of the cells usually survive, and these surviving cells may subsequently form the nidus of an imatinib-resistant GIST, often containing secondary KIT mutations (Antonescu et al., 2005; Heinrich et al., 2006). Therefore, novel systemic therapeutic approaches are needed to maximise GIST cell death. Targeting death receptors, such as Fas, is a promising anticancer strategy by which apoptotic cell death can be induced. Unfortunately, the introduction of therapies targeting Fas with agonistic antibodies has been hampered by liver toxicity (Ogasawara et al., 1993). Therefore, even when the therapeutic window is low, systemic use of MegaFasL could still have a beneficial effect in combination with imatinib. As many GISTs tend to metastasise in the abdominal cavity, potential liver toxicity by MegaFasL might be circumvented by intraperitoneal applications to prevent MegaFasL from reaching high levels in the circulation (Stewart et al., 2002; Etter et al., 2007). In this way, MegaFasL might be applied in combination with systemic imatinib. The abundant Fas expression in GISTs suggests that also MegaFasL alone might be an option for patients with primary or acquired resistance to imatinib. However, besides Fas membrane expression, one should take into account the expression of intracellular components affecting sensitivity to Fas-mediated apoptosis in these GISTs.

In conclusion, we have identified Fas as a uniformly expressed receptor in GIST, which may be used as a therapeutic target. This is supported by our in vitro studies, in which MegaFasL is a potent apoptosis-inducing agent that is even more efficient in combination with imatinib.

ACKNOWLEDGEMENTS

This study was supported by personal grants from the Dutch Cancer Society and the Netherlands Organisation for Health Research and Development to Bart Rikhof.
REFERENCES

Abrahams VM, Straszewski SL, Kamsteeg M, Hanczarak B, Schwartz PE, Rutherford TJ, Mor G (2003) Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 63: 5573 – 5581

Andreola G, Rivollini L, Castelli C, Huber V, Perego R, Deho P, Squarcina P, Accorneto P, Lonupone F, Lugini L, Stringari A, Mollinar A, Arancia G, Gentile M, Parmiani G, Fais S (2002) Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 195: 1303 – 1316

Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Korytowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP (2003) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182 – 4190

Arts HHJ, De Jong S, Hollema H, Ten Hoor KA, De Vries EG, Van der Zee AG (2005) Fas and Fas ligand in cyst fluids, serum and tumors of patients with benign and (borderline) malignant ovarian tumors. Int J Oncol 26: 379 – 384

Bauer S, Yu JX, Demetri GD, Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153 – 9161

Bellucco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L, Bianchi LC, Nitti D, Lise M (2002) Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 28: 120 – 125

Corless CL, Fletcher JA, Heinrich MC (2004) Biology of gastrointestinal stromal tumors. J Clin Oncol 22: 3831 – 3832

De Groot DJ, Timmer T, Spierings DC, Le TK, De Jong S, De Vries EG (2005) Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumscribes acquired doxorubicin resistance in SCLC cells. Br J Cancer 92: 1459 – 1466

Etter AL, Bassi I, Germain S, Delaloye IF, Tschopp J, Sordat B, Dupuis M (2007) The combination of chemotherapy and intraperitoneal MegaFas ligand improves treatment of ovarian carcinoma. Gynecol Oncol 107: 14 – 21

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O’Leary TJ, Remotti H, Rubin BP, Smookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459 – 465

Greney P, Nahimana A, Lagopoulois I, Etter AL, Aubry D, Attinger A, Beltraminelli N, Huni B, Bassi I, Sordat B, Demotz S, Dupuis M, Duchosal MA (2006) A Fas agonist induces high levels of apoptosis in haematologically malignant malignancies. Leuk Res 30: 415 – 426

Heinrich MC, Corless CL, Blanken DE, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, Von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764 – 4774

Heinrich MC, Corless CL, Duensing A, McMurry L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708 – 710

Heinrich MC, Rubin BP, Longley BJ, Fletcher JA (2002) Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33: 484 – 495

Holler N, Tardivel A, Kovaczewski-Bankowski M, Hertig P, Gaide O, Holler N, Tardivel A, Kovacicovska M, Ishii A, Seto Y, Nagata S (1991) The polypeptide encoded by the cDNA for the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor superfamily. Sequence cloning of the APO-1 cell surface antigen, a member of the nerve growth factor/necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of BcR-Abl-positive human acute leukemia cells. Clin Cancer Res 7: 350 – 357

Judson I, Demetri G (2007) Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol 18(Suppl 10): 2x0 – 2x4

Keller OT, Peter ME, Hindrich S, Molenhauer G, Stehling P, Schmitz I, Schwartz-Albiez R, Reutter W, Pawlita M (1999) Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotrophic virus. Glycobiology 9: 557 – 569

Keppler OT, Peter ME, Hindrich S, Molenhauer G, Stehling P, Schmitz I, Schwartz-Albiez R, Reutter W, Pawlita M (1999) Differential sialylation of cell surface glycoconjugates in a human B lymphoma cell line regulates susceptibility for CD95 (APO-1/Fas)-mediated apoptosis and for infection by a lymphotrophic virus. Glycobiology 9: 557 – 569

Lambert C, Landau AM, Desbarats J (2003) Fas-beyond death: a regenerative role for Fas in the nervous system. Apoptosis 8: 551 – 562

Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Lee HK, Park JY, Oh RR, Jang JI, Lee JY, Yoo NJ (1999) Immunohistochemical analysis of Fas ligand expression in normal human tissues. APMIS 107: 1013 – 1019

Leithauser F, Dhein J, Mechtcherishein G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P (1993) Constitutive and induced expression of APO-1, a new member of the nerve growth factor/fiber growth factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69: 415 – 429

Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B, Sahlbinska K, Kindblom LG (2005) Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer 103: 821 – 829

Nimmannapalli R, Porosnicu M, Nguyen D, Worthington E, O’Bryan E, Perkins C, Bhalla K (2001) Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of BcR-Abl-positive human acute leukemia cells. Clin Cancer Res 7: 350 – 357

Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Traub BC (1992) Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerv growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 276: 10709 – 10715

Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzaawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806 – 809

Reimer T, Herrengring K, Koczan D, Richter D, Gerber B, Kablitz D, Friese K, Thiesen HJ (2000) FasL: Fas ratio – a prognostic factor in breast carcinomas. Cancer Res 60: 822 – 828

Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187: 1205 – 1213

Stewart JH, Nguyen DM, Chen GA, Schrump DS (2002) Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apof(CD95)) death-signal pathway. J Thorac Cardiovasc Surg 123: 295 – 302

Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169 – 1178

Tepper CG, Seldin MF, Mudryj M (2000) Fas-mediated apoptosis of proliferating, transiently growth-arrested, and senescent normal human fibroblasts. Exp Cell Res 260: 9 – 19

Timmer T, De Vries EG, De Jong S (2002) Fas receptor-mediated apoptosis: a clinical application? J Pathol 206: 125 – 134

Tuveson DA, Willis NA, Grun JD, Singer D, Fletcher CD, Fletcher JA, Demetri GD (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054 – 5058

Verweij J, Casali PG, Zalgbjerg J, LeCesne A, Reichardt P, Blay JY, Issels R, Van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127 – 1134

Westra JW, Hollema H, Schaapveld M, Pattelee I, Oien KA, Keith WN, Mauritz R, Peters GJ, Buys CH, Hofstra RM, Plukker JT (2005) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 16: 1646 – 1653